Chris Buyse

Chris Buyse has over 30 years of expertise in international finance and financial management, and has been a member of the Board of Directors since February 2017. He was Chief Financial Officer (CFO) of the Belgian company CropDesign, where he coordinated the acquisition of BASF, and CFO of ThromboGenics, a biotechnology company listed on Euronext Brussels. He was previously CFO of Worldcom/MCI Belgium-Luxembourg and CFO, then Interim Chief Executive Officer of Keyware Technologies N.V. He has also held various positions within Spector Photo Group, Lyonnaise des Eaux (Suez) and Unilever. He is currently a member of the Board of Directors of several listed and private companies, in particular Celyad Oncology SA, EYE-D Pharma SA and Hyloris Pharmaceuticals SA.

He is also Managing Partner of the Belgian company Fund+ NV which he co-founded in 2015. Fund+ is an investment company investing in innovative biotech companies based in Europe and have currently more than EUR 200 M. under management.

Chris Buyse holds a Master’s in Applied Economics from the University of Antwerp, and a Master’s of Business Administration (MBA) from the Vlerick School of Management in Ghent.